key: cord-0063923-8o7uz5fg
authors: Vlok, Ruan A.; Melhuish, Thomas M.; Thang, Christopher; Askew, Judith; White, Leigh D.
title: The importance of meta-analysis to predict outcomes early in a pandemic: Extracorporeal membrane oxygenation and mortality
date: 2021-06-01
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2021.05.077
sha: 56ad1ea7980dd1c3743b2ceaabf4f53d77d5c559
doc_id: 63923
cord_uid: 8o7uz5fg

nan

In May 2020 our group published a brief systematic review and meta-analysis of 331 cases of COVID-19 treated with extracorporeal membrane oxygenation (ECMO) (1) . Since the publication of this brief meta-analysis, many studies have been published reporting the survival rates of patients with COVID-19 requiring ECMO. The most recent of which is a study titled 'Analysis of COVID-19 Patients with Acute Respiratory Distress Syndrome Managed with Extracorporeal Membrane Oxygenation at us Academic Centers' published in the Annals of Surgery (2) . This study reported in April 2021, in a cohort of 1,182 patients with COVID-19 induced refractory acute respiratory distress syndrome (ARDS) requiring ECMO with an in-hospital mortality rate of 45.9%. Furthermore, another recent study published in April 2021, in the Lancet Respiratory Medicine followed a similar cohort based in France to 90 days (3) . The results of this study showed a logically higher mortality rate due to the longer follow up period. Their study demonstrated a mortality rate of 54% for 302 patients with refractory ARDS due to COVID-19 treated with ECMO (2) . The mortality rates demonstrated in these studies differs significantly from the mortality rates reported early in 2020 (4).

During the initial period of the pandemic, there were calls for caution regarding the role of ECMO in COVID-19. This was due to the limited availability of data and variable reported results, with concern for potentially high mortality rates (4). This was reflected in the limited studies and databases available, which showed varying mortality rates ranging from 0-100% (1). This increased the uncertainty surrounding the efficacy of ECMO for the management of COVID-19.

In our pooled prevalence meta-analysis, the in-hospital mortality in COVID-19 patients requiring ECMO patients was 46% (95%CI=34-59%) (4). This represents a 0.1% difference to the reported mortality rate in the Annals of Surgery paper, which is inline with the 90 day mortality in the French cohort almost exactly a year later (2, 3) . This highlights the benefit of meta-analyses during this pandemic as a tool for rapid synthesis of data. Meta-analyses carry the additional benefit of 'rapid generalisability', as they represent a multicenter cohort with heterogeneity that can be analysed more rapidly than the traditional time required to undertake a multicenter study.

Outcomes of extracorporeal membrane oxygenation support for patients with COVID-19: A pooled analysis of 331 cases

Analysis of COVID-19 Patients with Acute Respiratory Distress Syndrome Managed with Extracorporeal Membrane Oxygenation at us Academic Centers. Annals of surgery

Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater

COVID-19, ECMO, and lymphopenia: a word of caution